359 related articles for article (PubMed ID: 34108958)
1. Intrinsic Resistance of Chronic Lymphocytic Leukemia Cells to NK Cell-Mediated Lysis Can Be Overcome
Wurzer H; Filali L; Hoffmann C; Krecke M; Biolato AM; Mastio J; De Wilde S; François JH; Largeot A; Berchem G; Paggetti J; Moussay E; Thomas C
Front Immunol; 2021; 12():619069. PubMed ID: 34108958
[TBL] [Abstract][Full Text] [Related]
2. Actin Cytoskeleton Remodeling Drives Breast Cancer Cell Escape from Natural Killer-Mediated Cytotoxicity.
Al Absi A; Wurzer H; Guerin C; Hoffmann C; Moreau F; Mao X; Brown-Clay J; Petrolli R; Casellas CP; Dieterle M; Thiery JP; Chouaib S; Berchem G; Janji B; Thomas C
Cancer Res; 2018 Oct; 78(19):5631-5643. PubMed ID: 30104240
[TBL] [Abstract][Full Text] [Related]
3. NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients: implication of HLA-G.
Maki G; Hayes GM; Naji A; Tyler T; Carosella ED; Rouas-Freiss N; Gregory SA
Leukemia; 2008 May; 22(5):998-1006. PubMed ID: 18288133
[TBL] [Abstract][Full Text] [Related]
4. NK Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications.
Sportoletti P; De Falco F; Del Papa B; Baldoni S; Guarente V; Marra A; Dorillo E; Rompietti C; Adamo FM; Ruggeri L; Di Ianni M; Rosati E
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206399
[TBL] [Abstract][Full Text] [Related]
5. Increased cytotoxicity against B-chronic lymphocytic leukemia by cellular manipulations: potentials for therapeutic use.
Vu UE; Pavletic ZS; Wang X; Joshi SS
Leuk Lymphoma; 2000 Nov; 39(5-6):573-82. PubMed ID: 11342340
[TBL] [Abstract][Full Text] [Related]
6. Reactive oxygen species induced by therapeutic CD20 antibodies inhibit natural killer cell-mediated antibody-dependent cellular cytotoxicity against primary CLL cells.
Werlenius O; Aurelius J; Hallner A; Akhiani AA; Simpanen M; Martner A; Andersson PO; Hellstrand K; Thorén FB
Oncotarget; 2016 May; 7(22):32046-53. PubMed ID: 27097113
[TBL] [Abstract][Full Text] [Related]
7. Actin Cytoskeleton Straddling the Immunological Synapse between Cytotoxic Lymphocytes and Cancer Cells.
Wurzer H; Hoffmann C; Al Absi A; Thomas C
Cells; 2019 May; 8(5):. PubMed ID: 31100864
[TBL] [Abstract][Full Text] [Related]
8. Soluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell anti-tumor activity.
Reiners KS; Topolar D; Henke A; Simhadri VR; Kessler J; Sauer M; Bessler M; Hansen HP; Tawadros S; Herling M; Krönke M; Hallek M; Pogge von Strandmann E
Blood; 2013 May; 121(18):3658-65. PubMed ID: 23509156
[TBL] [Abstract][Full Text] [Related]
9. Neutralization of (NK-cell-derived) B-cell activating factor by Belimumab restores sensitivity of chronic lymphoid leukemia cells to direct and Rituximab-induced NK lysis.
Wild J; Schmiedel BJ; Maurer A; Raab S; Prokop L; Stevanović S; Dörfel D; Schneider P; Salih HR
Leukemia; 2015 Aug; 29(8):1676-83. PubMed ID: 25710310
[TBL] [Abstract][Full Text] [Related]
10. NK cell function is markedly impaired in patients with chronic lymphocytic leukaemia but is preserved in patients with small lymphocytic lymphoma.
Parry HM; Stevens T; Oldreive C; Zadran B; McSkeane T; Rudzki Z; Paneesha S; Chadwick C; Stankovic T; Pratt G; Zuo J; Moss P
Oncotarget; 2016 Oct; 7(42):68513-68526. PubMed ID: 27655680
[TBL] [Abstract][Full Text] [Related]
11. Primary B-CLL resistance to NK cell cytotoxicity can be overcome in vitro and in vivo by priming NK cells and monoclonal antibody therapy.
Veuillen C; Aurran-Schleinitz T; Castellano R; Rey J; Mallet F; Orlanducci F; Pouyet L; Just-Landi S; Coso D; Ivanov V; Carcopino X; Bouabdallah R; Collette Y; Fauriat C; Olive D
J Clin Immunol; 2012 Jun; 32(3):632-46. PubMed ID: 22318393
[TBL] [Abstract][Full Text] [Related]
12. Glucocorticoid-induced TNFR-related protein (GITR) ligand modulates cytokine release and NK cell reactivity in chronic lymphocytic leukemia (CLL).
Buechele C; Baessler T; Wirths S; Schmohl JU; Schmiedel BJ; Salih HR
Leukemia; 2012 May; 26(5):991-1000. PubMed ID: 22064350
[TBL] [Abstract][Full Text] [Related]
13. Expanded and activated allogeneic NK cells are cytotoxic against B-chronic lymphocytic leukemia (B-CLL) cells with sporadic cases of resistance.
Calvo T; Reina-Ortiz C; Giraldos D; Gascón M; Woods D; Asenjo J; Marco-Brualla J; Azaceta G; Izquierdo I; Palomera L; Sánchez-Martínez D; Marzo I; Naval J; Vilches C; Villalba M; Anel A
Sci Rep; 2020 Nov; 10(1):19398. PubMed ID: 33173077
[TBL] [Abstract][Full Text] [Related]
14. Ig-Like Transcript 2 (ILT2) Blockade and Lenalidomide Restore NK Cell Function in Chronic Lymphocytic Leukemia.
Villa-Álvarez M; Sordo-Bahamonde C; Lorenzo-Herrero S; Gonzalez-Rodriguez AP; Payer AR; Gonzalez-Garcia E; Villa-Álvarez MC; López-Soto A; Gonzalez S
Front Immunol; 2018; 9():2917. PubMed ID: 30619281
[TBL] [Abstract][Full Text] [Related]
15. Lenalidomide induces immunomodulation in chronic lymphocytic leukemia and enhances antitumor immune responses mediated by NK and CD4 T cells.
Acebes-Huerta A; Huergo-Zapico L; Gonzalez-Rodriguez AP; Fernandez-Guizan A; Payer AR; López-Soto A; Gonzalez S
Biomed Res Int; 2014; 2014():265840. PubMed ID: 25313353
[TBL] [Abstract][Full Text] [Related]
16. Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies.
Le Garff-Tavernier M; Decocq J; de Romeuf C; Parizot C; Dutertre CA; Chapiro E; Davi F; Debré P; Prost JF; Teillaud JL; Merle-Beral H; Vieillard V
Leukemia; 2011 Jan; 25(1):101-9. PubMed ID: 20975664
[TBL] [Abstract][Full Text] [Related]
17. A targeted siRNA screen identifies regulators of Cdc42 activity at the natural killer cell immunological synapse.
Carlin LM; Evans R; Milewicz H; Fernandes L; Matthews DR; Perani M; Levitt J; Keppler MD; Monypenny J; Coolen T; Barber PR; Vojnovic B; Suhling K; Fraternali F; Ameer-Beg S; Parker PJ; Thomas NS; Ng T
Sci Signal; 2011 Nov; 4(201):ra81. PubMed ID: 22126964
[TBL] [Abstract][Full Text] [Related]
18. 4-1BB ligand modulates direct and Rituximab-induced NK-cell reactivity in chronic lymphocytic leukemia.
Buechele C; Baessler T; Schmiedel BJ; Schumacher CE; Grosse-Hovest L; Rittig K; Salih HR
Eur J Immunol; 2012 Mar; 42(3):737-48. PubMed ID: 22144129
[TBL] [Abstract][Full Text] [Related]
19. Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer.
Ramsay AG; Clear AJ; Fatah R; Gribben JG
Blood; 2012 Aug; 120(7):1412-21. PubMed ID: 22547582
[TBL] [Abstract][Full Text] [Related]
20. The PI3K∂-Selective Inhibitor Idelalisib Induces T- and NK-Cell Dysfunction Independently of B-Cell Malignancy-Associated Immunosuppression.
Rohrbacher L; Brauchle B; Ogrinc Wagner A; von Bergwelt-Baildon M; Bücklein VL; Subklewe M
Front Immunol; 2021; 12():608625. PubMed ID: 33790890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
